By means of human growth hormone-releasing hormone (hGHRH)-RIA
and Rivier et al. (1982) have independently isolated human GH-releasing hormone (hGHRH) from human pancreatic tumors that had caused acromegaly. hGHRH has been reported to be a potent and specific secretagogue of GH in human as well as animals (Chihara et al., 1985; Chihara et al., 1983) . Although the availability of synthetic hGHRH offers a useful tool not only for the understanding of the regulatory mechanism of GH release but also for the diagnosis of hypothalamopituitary diseases, the fate of exogenously administered hGHRH in plasma remains to be not fully clarified. At present, only one study using hGHRH-(1-40)-OH on hGHRH clearance from the plasma has been reported in normal men (Frohman et al., 1984) , suggesting a longer half-life of synthetic hGHRH-(1-40)-OH than other hypothalamic hormones such as GnRH (Jeffcoate et al., 1974) , TRH (Morley et al., 1979) and human (rat) CRF (Schuermeyer et al., 1984) . However, the plasma disappearance half-time and metabolic clearance rate of hGHRH-(1-44)-NH2 remain unknown. Disappearance half-time, MCR and volume of distribution of IR-hGHRH IR-hGHRH was undetectable in plasma (less than 50 pg/ml) in any subjects before they received hGHRH-(1-44)-NH2.
An iv bolus injection of hGHRH-(1-44)-NH2 (1 pg/kg BW) resulted in a prompt rise in plasma IR-hGHRH with a mean + SE value 11.2+1.6 ng/ml at 1 minute after the injection. Measurable IR-hGHRH levels were then sustained for approximately 90 min with a gradual decline (Fig. 2) . This disappearance pattern of plasma IR-hGHRH could be fitted to a biexpotential decay curve in all 10 subjects. The parameters calculated from individual values are shown in Table 1 . The a andphase t-1 values (mean + SE) were 5.0+1.0 and 29.6+ 5.4 min, respectively. The MCR of IR-hGHRH ranged from 2.2-14.6 ml/min • kg with a mean + SE value of 6.1 +1.2 ml/min • kg (315+184 liters/m2/d). The initial volume of distribution of hGHRH was 3.3+0.4 liters. Table 1 . Plasma IR-hGHRH kinetics in normal subjects to whom hGHRH-(1-44)-NH2 was injected iv as a volus dose of 1 pg/kg BW.
Note. t12, half-time of disappearance from plasma (a and(i,first and second phases of disappearance, respectively) MCR, metabolic clearance rate Vd, volume of distribution
Gel-filtration pattern of IR-hGHRH in plasma after hGHRH-(1-44)-NH2 injection The plasma obtained 30, 45 and 90 min after hGHRH-(1-44)-NH2 injection in a subject (no. 10) was applied to a Sephadex G-50 column.
The volume of applied plasma was 0.5, 0.8 and 2.0 ml of the samples collected 30, 45 and 90 min, respectively, after hGHRH injection. Most of the IR-hGHRH in the plasma obtained 30, 45 and 90 min after the administration eluted in fractions which corresponded to the elution position of hGHRH-(1-44)-NH2 standard (Fig. 3) . When the volume of applied plasma was large, the chromatographic main peak of IR-hGHRH was broad and rugged, as shown in B and C of Fig. 3 .
Discussion
In order to define the pharmacockinetic properties of circulating hGHRH-(1-44)-NH2 in normal subjects, the plasma samples frequently collected after iv injection of hGHRH-(1-44)-NH2
were measured by radioimmunoassay using antiserum specific to the C-terminal portion of hGHRH-(1-44)-NH2. Since the antigenic determinant ability of our antiserum was so sensitive as to distinguish the amide of the C-terminal leucine residue, even the relatively big Nterminal peptides like hGHRH-(1-37)-OH and -(1-40)-OH were not detectable in our RIA method.
On the contrary, cross- 6,2 and 6.1 min calculated for GnRH, TRH and ovine CRF, respectively (Jeffcoate et al., 1974; Morley et al., 1979; Nicholson et al., 1983) . However,a t1/2 of hGHRH- 
